MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, VTVT had $72,582K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$72,582K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss before noncontrolling interest
-10,345 -13,597
Depreciation expense
2 12
Share-based compensation expense
1,007 1,743
Change in fair value of warrants-Related Party
6 -26
Change in fair value of warrants-Nonrelated Party
34 5
Prepaid expenses
481 -833
Other current assets
19 -82
Other assets
-34 -67
Accounts payable and accrued expenses
4,587 189
Other liabilities
-47 -90
Net cash used in operating activities
-5,222 -10,782
Proceeds from sale of class a common stock, pre-funded and common warrants, net of offering costs
77,476 -
Proceeds from sale of class a common stock and pre-funded warrants, net of offering costs
0 0
Proceeds from issuance of class a common stock, net of offering costs
0 -
Proceeds from the exercise of stock options
0 9
Taxes paid related to net share settlement of equity awards
0 51
Proceeds from debt issuance
392 -
Repayment of notes payable
64 0
Net cash provided by financing activities
77,804 -42
Net increase in cash and cash equivalents
72,582 -10,824
Cash and cash equivalents at beginning of period
36,746 -
Cash and cash equivalents at end of period
98,504 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Inc. (VTVT)